New drug KP-001 put to the heart safety test

NCT ID NCT06649942

Completed Knowledge-focused Sponsor: Kaken Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study checks whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control drug known to affect the QT interval) in random order. The goal is to see if KP-001 causes any heart rhythm changes, which is a key safety step before testing the drug for medical conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KP-001
What this could lead to: If this study shows KP-001 does not affect heart rhythm, it could support further development of the drug for its intended use.
What could go wrong: This is an early Phase 1 safety study in healthy volunteers, not designed to test effectiveness. The drug may still cause heart rhythm changes or other side effects in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS - MALE AND FEMALE

Contacts and locations

Locations

Parexel Early Phase Clinical Unit - Los Angeles

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.